Physician profile
Mark Reisman
NPI 1952460826
$223,997.51
in general payments reported to CMS, 2019-2025
16 companies · $13K in 2025
The $13K reported for 2025 was more than what 90% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $10K · 2021: $2,940 · 2022: $10K · 2023: $146K · 2024: $13K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $126K · Travel and Lodging: $21K · Food and Beverage: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,500 · Consulting Fee: $2,500 · Long Term Medical Supply Or Device Loan: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $125,741.99 |
| Travel and Lodging | $21,368.21 |
| Food and Beverage | $14,406.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,500.00 |
| Consulting Fee | $2,500.00 |
| Long Term Medical Supply Or Device Loan | $281.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $125,684.49 | 2023 | |
| Ancora Heart, INC. | $51,901.72 | 2019-2025 | Accucinch |
| Boston Scientific Corporation | $21,481.31 | 2019-2025 | Versacross Access Solution, Avvigo Guidance System, Farawave |
| Abbott Laboratories | $10,161.59 | 2019-2025 | Mitraclip, Navitor, Portico |
| Medtronic Vascular, INC. | $6,566.33 | 2019-2020 | |
| Edwards Lifesciences Corporation | $5,422.37 | 2019-2025 | Sapien 3 Ultra Resilia, Pascal, Evoque |
| Medtronic, INC. | $1,584.34 | 2022-2025 | Corevalve Evolut R, Abre, Onyx Frontier |
| Siemens Medical Solutions USA, INC. | $459.98 | 2021 | |
| Jenavalve Technology, INC. | $162.06 | 2023 | Jenavalve Pericardial Tavr System |
| Abiomed | $150.00 | 2022 | |
| Endologix LLC | $150.00 | 2025 | Endocross Device, Torus Stent Graft System |
| Arrow International, INC. | $144.85 | 2019 | |
| Shockwave Medical, INC | $102.67 | 2022 | |
| Scpharmaceuticals INC. | $25.80 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Reisman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.